Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Chief Accounting Officer | October 04, 2016 | October 06, 2016 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | SVP, Finance and CAO | August 06, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date October 04, 2016 · Filed October 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,839 |
Reported balance
After 2016-10-04 transaction · row 1
1 source rowRow 1 · 2016-10-04 · Grant · Acquired 1,839 · Balance 1,839 F1: Shares are represented by restricted stock units. Shares of restricted common stock vest in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.19 · Expires 2026-10-04 | Direct | 5,856 |
Reported balance
After 2016-10-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-10-04 · Grant · Acquired 5,856 · Balance 5,856 F2: The option vests in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are represented by restricted stock units. Shares of restricted common stock vest in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017.
F2: The option vests in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,852 |
Ending reported balance
After 2026-08-06 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-08-06 · Sale · Disposed 1,274 · Balance 14,878 F1: This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 2 · 2026-08-06 · Sale · Disposed 901 · Balance 13,977 F2: This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-06 · Sale · Disposed 810 · Balance 13,167 F3: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-08-06 · Sale · Disposed 213 · Balance 12,954 F4: This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-08-06 · Sale · Disposed 620 · Balance 12,334 F5: This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-08-06 · Sale · Disposed 482 · Balance 11,852 F6: This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-08-06 · Exercise / conversion · Acquired 404 · Balance 12,256 Row 8 · 2026-08-06 · Exercise / conversion · Acquired 1,205 · Balance 13,461 Row 9 · 2026-08-06 · Exercise / conversion · Acquired 736 · Balance 14,197 Row 10 · 2026-08-06 · Sale · Disposed 404 · Balance 13,793 Row 11 · 2026-08-06 · Sale · Disposed 1,205 · Balance 12,588 Row 12 · 2026-08-06 · Sale · Disposed 736 · Balance 11,852 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $179.66 · Expires 2030-05-29 | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-06 · Exercise / conversion · Disposed 404 · Balance 0 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $194.12 · Expires 2033-05-26 | Direct | 402 |
Reported balance
After 2026-08-06 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-08-06 · Exercise / conversion · Disposed 1,205 · Balance 402 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.44 · Expires 2034-05-31 | Direct | 736 |
Reported balance
After 2026-08-06 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-08-06 · Exercise / conversion · Disposed 736 · Balance 736 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $258.77 to $259.43. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: This transaction was executed in multiple trades at prices ranging from $259.97 to $260.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $261.00 to $261.84. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $262.26 to $262.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $263.39 to $264.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $264.91 to $265.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2020 Filed Jun 2, 2020 18:15 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018388 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,414 F1 · shares: Unvested restricted stock units vest in one-fourth increments on May 29, 2021, 2022, 2023 and 2024. Read SEC document |
| May 01, 2020 Filed May 4, 2020 16:27 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 62 | $144.67 | $8,969.54 |
DisclosureSEC source: 0001127602-20-015124 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 Read SEC document |
| February 23, 2020 Filed Feb 24, 2020 17:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 56 | $173.64 | $9,723.84 |
DisclosureSEC source: 0001127602-20-007121 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,992 Read SEC document |
| February 22, 2020 Filed Feb 24, 2020 17:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 51 | $173.64 | $8,855.64 |
DisclosureSEC source: 0001127602-20-007121 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048 Read SEC document |
| May 01, 2019 Filed May 1, 2019 17:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 62 | $140.47 | $8,709.14 |
DisclosureSEC source: 0001127602-19-016669 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099 Read SEC document |
| February 23, 2019 Filed Feb 26, 2019 19:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 56 | $144.67 | $8,101.52 |
DisclosureSEC source: 0001127602-19-008318 · form4.xml · nonDerivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,161 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 2,941 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-19-008318 · form4.xml · derivative · entry 3 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941 Underlying: Common Stock · 2,941 shares Expires 2024-02-22 F2 · derivative.exercise_date: Stock options vest as follows: 735 options vest one (1) year from the date of grant, 735 options vest two (2) years from the date of grant, 735 options vest (3) years from the date of grant, and 736 options vest four (4) years from the date of grant. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 19:44 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 690 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008318 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,217 F1 · security: Consists of 690 unvested restricted stock units that vest as follows: 172 shares vest one (1) year from the date of issuance, 173 shares vest two (2) years from the date of issuance, 172 shares vest three (3) years from the date of issuance, and 173 shares vest four (4) years from the date of issuance. Read SEC document |
| May 01, 2018 Filed May 1, 2018 20:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 61 | $104.19 | $6,355.59 |
DisclosureSEC source: 0001127602-18-015752 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,527 Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 18:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 3,419 | $0.00 Strike: $109.34 | $0.00 |
DisclosureSEC source: 0001127602-18-008322 · form4.xml · derivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,419 Underlying: Common Stock · 3,419 shares Expires 2023-02-23 F2 · derivative.exercise_date: Stock options vest as follows: 854 options vest one (1) year from the date of grant, 855 options vest two (2) years from the date of grant, 855 options vest three (3) years from the date of grant, and 855 options vest four (4) years from the date of grant. Read SEC document |
| February 23, 2018 Filed Feb 26, 2018 18:57 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 758 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008322 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,588 F1 · security: Consists of 758 unvested restricted stock units that vest as follows: 189 shares vest one (1) year from the date of issuance, 190 shares vest two (2) years from the date of issuance, 189 shares vest three (3) years from the date of issuance and 190 shares vest four (4) years from the date of issuance. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 1,330 | $0.00 Strike: $90.43 | $0.00 |
DisclosureSEC source: 0001127602-17-016577 · form4.xml · derivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 Underlying: Common Stock · 1,330 shares Expires 2022-05-01 F2 · derivative.exercise_date: Stock options vest as follows: 332 options vest one (1) year from the date of grant, 333 options vest two (2) years from the date of grant, 332 options vest three (3) years from the date of grant, and 333 options vest four (4) years from the date of grant. Read SEC document |
| May 01, 2017 Filed May 3, 2017 19:08 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 830 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-016577 · form4.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · CSVP&Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 830 F1 · security: Consists of 830 unvested restricted stock units that vest as follows: 207 shares vest one (1) year from the date of issuance, 208 shares vest two (2) years from the date of issuance, 207 shares vest three (3) years from the date of issuance and 208 shares vest four (4) years from the date of issuance. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 17:27 UTC | BRUKER CORP BRKR · Entity 3609 | GrantStock Option (Right to Buy) · Derivative | 5,856 | $0.00 Strike: $22.19 | $0.00 |
DisclosureSEC source: 0001179110-16-030517 · edgar.xml · derivative · entry 2 Knell Michael Gunnar · CIK 0001543779 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,856 Underlying: Common Stock · 5,856 shares Expires 2026-10-04 F2 · derivative.exercise_date: The option vests in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. Read SEC document |
| October 04, 2016 Filed Oct 6, 2016 17:27 UTC | BRUKER CORP BRKR · Entity 3609 | GrantCommon Stock | 1,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030517 · edgar.xml · nonDerivative · entry 1 Knell Michael Gunnar · CIK 0001543779 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,839 F1 · shares: Shares are represented by restricted stock units. Shares of restricted common stock vest in four approximately equal annual installments on the anniversary of the grant date, commencing October 4, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.